While a large number of mTOR inhibitors have been developed and are being evaluated in clinical trials in lung cancer, neither of sirolimus, temsirolimus, or everolimus, when used as monotherapeutic agents, show clinical efficacy in unselected NSCLC [46], [47]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.